Insmed raises peak sales guidance to $14 billion
Insmed (INSM) raised peak sales guidance to $14 billion, citing strong BRINSUPRI and TPIP performance and expanding indications. It expects profitability next year.
Peak sales guidance was raised to $14 billion, driven by strong BRINSUPRI and TPIP performance and expanding indications. The BRINSUPRI launch exceeded benchmarks, with rapid patient uptake, high payer approval, and growing market potential. Based on Insmed Incor…